The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.
The most advanced malaria vaccine, RTS,S, is comprised of a portion of the Plasmodium falciparum circumsporozoite (CS) protein, fused to and admixed with the hepatitis B virus surface antigen, and an adjuvant [corrected].This vaccine confers short-term protection against malaria infection, with an efficacy of about 50%, and induces particularly B-cell and CD4(+) T-cell responses.In the present study, we tested the hypothesis that the Th1 immune response to CS protein,in particular the CD8(+) T-cell response, which is needed for strong and lasting malaria immunity, is boosted to sustainable levels by adenovirus vectors 35 and 26 with a homologous insert (Ad35.CS/Ad26.CS) [corrected]. In this study, we evaluated immune responses induced with vaccination regimens based on an adjuvant-containing, yeast-produced complete CS protein followed by two recombinant low-seroprevalence adenoviruses expressing P. falciparum CS antigen, Ad35.CS (subgroup B) and Ad26.CS (subgroup D). Our results show that (i) the yeast (Hansenula polymorpha)produced, adjuvanted full-length CS protein is highly potent in inducing high CS-specific humoral responses in mice but produces poor T-cell responses, (ii) the Ad35.CS vector boosts the gamma interferon-positive (IFN-γ(+)) CD8(+) T-cell response induced by the CS protein immunization and shifts the immune response toward the Th1 type, and (iii) a three-component heterologous vaccination comprised of a CS protein prime followed by boosts with Ad35.CS and Ad26.CS elicits an even more robust and sustainable IFN-γ(+) CD8(+) T-cell response than one- or two-component regimens. The Ad35.CS/Ad26.CS combination boosted particularly the IFN-γ(+) and tumor necrosis factor alpha-positive (TNF-α(+)) T cells, confirming the shift of the immune response from the Th2 type to the Th1 type. These results support the notion of first immunizations of infants with an adjuvanted CS protein vaccine, followed by a booster Ad35.CS/Ad26.CS vaccine at a later age, to induce lasting protection against malaria for which the Th1 response and immune memory is required.
Radosevic
Katarina
K
Crucell Holland B.V., Archimedesweg 4-6, 2333 CN Leiden, Netherlands. katarina.radosevic@crucell.com
Rodriguez
Ariane
A
Lemckert
Angelique A C
AA
van der Meer
Marjolein
M
Gillissen
Gert
G
Warnar
Carolien
C
von Eyben
Rie
R
Pau
Maria Grazia
MG
Goudsmit
Jaap
J
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D007371:Interferon-gamma / Q000378:metabolism; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010843:Pichia / Q000235:genetics; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology*; D014611:Vaccination / Q000379:methods; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; C041595:circumsporozoite protein, Protozoan; D007371:Interferon-gamma
J Immunol. 2009 Mar 15;182(6):3469-81
19265125
J Infect Dis. 2006 Dec 15;194(12):1638-49
17109335
J Clin Invest. 2009 Aug;119(8):2379-87
19620772
J Gen Virol. 2006 Oct;87(Pt 10):2891-2899
16963747
N Engl J Med. 2008 Dec 11;359(24):2521-32
19064627
PLoS Pathog. 2008 Sep 19;4(9):e1000159
18802458
PLoS Pathog. 2008 Feb 29;4(2):e1000004
18401464
Vaccine. 2009 Oct 19;27(44):6226-33
19686691
Vaccine. 2008 Feb 20;26(8):1072-82
18258343
Am J Trop Med Hyg. 2005 Jul;73(1):222-8
16014863
J Clin Invest. 2009 Jul;119(7):1899-909
19509469
J Virol. 2007 May;81(9):4654-63
17329340
Vaccine. 2006 May 22;24(21):4471-4
16140432
Nature. 2002 Jan 17;415(6869):331-5
11797011
J Immunol. 2004 May 15;172(10):6290-7
15128818
Infect Immun. 2006 Apr;74(4):2187-95
16552049
J Virol. 2008 May;82(10):4844-52
18337575
Nature. 2009 Jan 1;457(7225):87-91
18997770
Gastroenterology. 2009 Jan;136(1):247-56
18948106
Vaccine. 2002 Jan 15;20(7-8):1039-45
11803063
Clin Infect Dis. 2008 Jun 1;46(11):1769-81
18433307
Vaccine. 2008 Apr 24;26(18):2191-202
18387719
J Virol. 2003 Aug;77(15):8263-71
12857895
J Immunol. 1997 Feb 1;158(3):1268-74
9013969
Nat Rev Microbiol. 2006 Jun;4(6):469-76
16710326
Nat Med. 2008 Mar;14(3):275-81
18264110
Annu Rev Med. 2004;55:355-72
14746526
J Exp Med. 1994 Jul 1;180(1):353-8
7516412
J Gen Virol. 2006 Aug;87(Pt 8):2135-2143
16847108
Am J Med Sci. 1973 Sep;266(3):169-77
4583408
Expert Rev Vaccines. 2009 May;8(5):577-92
19397415
J Immunol. 2003 Feb 1;170(3):1416-22
12538702
Infect Immun. 2007 May;75(5):2283-90
17307942
Infect Immun. 2006 Jan;74(1):313-20
16368986
Infect Immun. 2007 Aug;75(8):4105-15
17526747
Vet Immunol Immunopathol. 2006 Dec 15;114(3-4):259-72
17045659
J Infect Dis. 2009 Aug 1;200(3):337-46
19569965
Infect Immun. 2008 Apr;76(4):1709-18
18212075
J Immunol. 2003 Dec 15;171(12):6774-9
14662882
Gastroenterology. 2009 Jun;136(7):2237-2246.e1
19272385
Curr Mol Med. 2006 Mar;6(2):169-85
16515509
J Virol. 2004 Dec;78(23):13207-15
15542673
Scand J Immunol. 2002 Oct;56(4):327-43
12234254
Immunol Rev. 2008 Oct;225:272-83
18837788
Nature. 2006 May 11;441(7090):239-43
16625206
Vaccine. 2008 Jul 4;26(29-30):3640-6
18514980
Proc Natl Acad Sci U S A. 1988 Jan;85(2):573-6
2963334
Int Immunol. 1991 Jun;3(6):579-85
1716146
Vaccine. 2007 Feb 9;25(8):1426-36
17161889
J Infect Dis. 2008 Feb 15;197(4):519-26
18275273
Nature. 1987 Dec 17-23;330(6149):664-6
3120015
Vaccine. 2009 Dec 30;27 Suppl 6:G67-71
20006143
Mol Ther. 2004 Oct;10(4):616-29
15451446
Nat Immunol. 2007 Apr;8(4):369-77
17351619
J Virol. 2004 Jul;78(14):7490-7
15220422
J Immunol. 2005 Jul 15;175(2):788-95
16002675
J Virol. 2004 Oct;78(20):11434-8
15452269